Cargando…
Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
Multiple myeloma (MM) is an incurable plasma cell malignancy with a heterogeneous genetic background. Each MM subtype may have its own therapeutic vulnerabilities, and tailored therapy could improve outcomes. However, the cumulative frequency of druggable targets across patients is very low, which h...
Autores principales: | Sklavenitis-Pistofidis, Romanos, Getz, Gad, Ghobrial, Irene, Papaioannou, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331166/ https://www.ncbi.nlm.nih.gov/pubmed/35912171 http://dx.doi.org/10.3389/fonc.2022.961421 |
Ejemplares similares
-
Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019) -
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2023) -
Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis
por: Boiarsky, Rebecca, et al.
Publicado: (2022) -
P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022) -
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)